REPURPOSE: PHASE II STUDY ASSESSING THE EFFICACY OF EFAVIRENZ, AN APPROVED HIV DRUG REPURPOSED AS AN ANTI-CANCER AGENT, IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER
Janine Lombard(Calvary Mater Newcastle Hospital), Nikola A. Bowden(Hunter Medical Research Institute), Hiren Mandaliya(Lake Macquarie Private Hospital), Jana Stojanova(St Vincent's Hospital Sydney), Kathryn Alsop(Peter MacCallum Cancer Centre), Mathias Bressel(Peter MacCallum Cancer Centre), Gaik Tin Quah(Calvary Mater Newcastle Hospital), Deborah J. Marsh(University of Technology Sydney), Philip Beale(The University of Sydney), Caroline E. Ford(UNSW Sydney), Rachel Campbell(South Eastern Health and Social Care Trust), Leanna Pugliese(Calvary Mater Newcastle Hospital), Tarek Meniawy(St John of God Subiaco Hospital), Giovana Cellimarchett(Manning Applied Technology (United States)), Brian Kelly(University of Newcastle Australia), Megan S Jeon(The University of Sydney), Karen Briscoe(Northern Cancer Institute), Lisa Beatty(Flinders University), G. Ritchie(Port Macquarie Base Hospital), Gill Stannard(Cooperative Trials Group for Neuro-Oncology), Alison M Davis(University of Canberra)
Cited by 0
Related Papers
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
BCL-2 family isoforms in apoptosis and cancer
|Cell Death and Disease|2019|706